Mavorixafor

N/A

Report date: 2026/05/13 20:02:10
NMEFirst In Class

Base Information

Drug NameMavorixafor
Drug Alias NameXolremdiXOLREMDIX4P-001-IOAMD-11070AMD-070 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonistsCytotoxic T lymphocytes stimulants
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsWHIM syndromeNeutropeniaHepatic Insufficiency +[8] 
Global Approved IndicationsWHIM syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/04/26
Country/TerritoryCzechiaCanadaUnited States +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesABbisko Therapeutics Co LtdX4 Pharmaceuticals (Austria) GmbhNorgine +[5] 
Inactive CompaniesGenzyme CorpNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsWHIM syndromeNeutropeniaHepatic Insufficiency +[6] 
Inactive IndicationsMelanomaHIV Infections

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG